ELI LILLY AND COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ELI LILLY AND COMPANY (LLY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $442.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-12
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $442.00M, a 21.91% decline from fiscal 2024.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $566.00M, a 16.40% decline from fiscal 2023.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $677.00M, a 891.22% increase from fiscal 2022.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $68.30M, a 550.48% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $442.00M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $566.00M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $677.00M 10-K · filed 2026-02-12 | $677.20M 10-K · filed 2024-02-21 |
| 2022-12-31 | $68.30M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $10.50M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $63.20M 10-K · filed 2021-02-17 | |
| 2019-12-31 | $0.00 10-K · filed 2021-02-17 | |
| 2018-12-31 | $309.90M 10-K · filed 2021-02-17 | |
| 2017-12-31 | $300.10M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $0.00 8-K · filed 2019-10-24 | |
| 2015-12-31 | $0.00 10-K · filed 2018-02-20 | |
| 2010-12-31 | $0.00 10-K · filed 2011-02-22 | |
| 2009-12-31 | $0.00 10-K · filed 2011-02-22 | |
| 2008-12-31 | $1.82B 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |